venBio Global Strategic Fund III, L.P. - Jul 18, 2024 Form 3 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
10%+ Owner
Signature
venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ Antoinette Delhonte, as attorney-in-fact
Stock symbol
ARTV
Transactions as of
Jul 18, 2024
Transactions value $
$0
Form type
3
Date filed
7/18/2024, 08:14 PM
Previous filing
Sep 21, 2023
Next filing
Jul 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARTV Series A Preferred Stock Jul 18, 2024 Common Stock 844K Direct F1
holding ARTV Series B Preferred Stock Jul 18, 2024 Common Stock 215K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F2 These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein.

Remarks:

Dr. Aaron Royston is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III. Exhibit 24 - Power of Attorney.